The t:slim has a vivid color touch screen with a programmable insulin infusion pump, utilizing proprietary micro-delivery technology through which insulin is delivered from a 300-unit cartridge.
DexCom will receive a technology license fee of $3m from Tandem, which will also reimburse DexCom’s development, clinical and regulatory expenses.
Tandem said it will pay DexCom a royalty of $100 for each CGM-enabled insulin pump, upon commercialization of the combined system.
DexCom CEO Terrance Gregg said they are very pleased to work with Tandem to help people with diabetes live longer, healthier lives.
Tandem president and CEO Kim Blickenstaff said through the development of t:slim, Tandem learned that design and ease of use are critically important to people with diabetes.
"DexCom’s future generation sensor adds to our portfolio approach of listening to people with diabetes and developing products that support their needs," Blickenstaff said.
